POG 9426 TREATMENT OF HODGKINS DISEASE WITH DBVE AND IRRADIATION

POG 9426 用 DBVE 和辐射治疗霍奇金病

• 批准号: 6279252
• 负责人: FAITH H KUNG
• 金额: $ 1.43万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279252
• 关键词: Hodgkin's disease; bleomycin; cardiopulmonary disease; clinical research; combination therapy; cytotoxicity; doxorubicin; drug adverse effect; human subject; human therapy evaluation; myocardium disorder; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; vincristine

POG 9426 to examine activity of variable courses of doxorubicin, bleomycin, vincristine, andetoposide (DBVE) and low dose involved field irradiation in treatment of early stage hodgkin's disease. Evaluate acute and chronic toxicities, examine if addition of zinecard can reduce cardiopulmonary toxicity and determine if frequency and magnitude of myocardial injury during therapy is reduced by addition of zinecard.

POG 9426检查阿霉素可变课程的活动， 博来霉素，长春新碱，苯托托剂（DBVE）和低剂量涉及场 治疗早期霍奇金氏病的辐照。评估急性 和慢性毒性，检查ZineCard的添加是否可以减少 心肺毒性，并确定频率和幅度是否 通过添加Zinecard减少治疗过程中的心肌损伤。